GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ --

Fourth quarter

   -- Sales of SEK 891 (959) million, organic growth in local currencies 
      excluding discontinued business* were 6%, 3% growth in local currencies 
      and 7% decrease in SEK, due to a significant currency impact of -10%. 
 
   -- Sales per region, in local currencies, were -1% in EMEA excluding 
      discontinued business, +9% in Americas and +10% in APAC. 
 
   -- Sales per product group, in local currencies excluding discontinued 
      business, were +10% in Consumables, +6% in Technologies and +1% in 
      Genetics. 
 
   -- Gross margin decreased to 58.0% (61.1). Gross margin excluding 
      restructuring costs was 58.6% (61.1). 
 
   -- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 
      196 (337) million, resulting in an EBITDA margin of 22.0% (35.1). EBITDA 
      excluding restructuring costs amounted to SEK 251 (337) million, 
      resulting in an EBITDA margin of 28.2% (35.1) impacted by negative 
      currency effect. 
 
   -- Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and 
      SEK 49 million in operating expenses. 
 
   -- An impairment charge of SEK 5,357 million was reported as other operating 
      expenses. 
 
   -- Net income amounted to SEK -5,314 (139) million, resulting in earnings 
      per share of SEK -39.24 (1.02). Net income excluding the impairment 
      charge and restructuring costs amounted to SEK 89 million (139), 
      resulting in earnings per share of SEK 0.66 (1.02). 
 
   -- Operating cash flow amounted to SEK 160 (268) million. 

Full year

   -- Sales of SEK 3,440 (3,609) million, organic growth in local currencies 
      excluding discontinued business was 4%, 2% growth in local currencies and 
      5% decrease in SEK, due to a significant currency impact of -6%. 
 
   -- Sales per region, in local currencies, were +5% in EMEA excluding 
      discontinued business, +8% in Americas and -1% in APAC. 
 
   -- Sales per product group, in local currencies excluding discontinued 
      business, were +8% in Consumables, +1% in Technologies and +3% in 
      Genetics. 
 
   -- Gross margin decreased to 58.1% (59.3). Gross margin excluding 
      restructuring costs was 58.2% (59.3). 
 
   -- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 
      949 (1,225) million, resulting in an EBITDA margin of 27.6% (34.0). 
      EBITDA excluding restructuring costs amounted to SEK 1,004 (1,225) 
      million, resulting in an EBITDA margin of 29.2% (34.0) significantly 
      impacted by negative currency effect. 
 
   -- Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and 
      SEK 49 million in operating expenses. 
 
   -- An impairment charge of SEK 5,357 million was reported as other operating 
      expenses. 
 
   -- Net income amounted to SEK -5,013 (514) million, resulting in earnings 
      per share of SEK -37.01 (3.78). Net income excluding the impairment 
      charge and restructuring costs amounted to SEK 390 million (514), 
      resulting in earnings per share of SEK 2.89 (3.78). 
 
   -- Operating cash flow amounted to SEK 635 (907) million. 

Dividend

   -- The Board to propose to the Annual General Meeting a dividend of SEK 149 
      (149) million, corresponding to SEK 1.10 (1.10) per share.* Discontinued 
      business refers to discontinued activities in certain markets in EMEA. 

Gothenburg, February 3, 2026

VITROLIFE AB (publ)

Bronwyn Brophy O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2026 08:00 CET.

CONTACT:

Amelie Wilson,

Investor relations,

external corporate communications and executive support,

awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/fourth-quarter-and-full-year-report-2025,c4301569

The following files are available for download:

 
https://mb.cision.com/Main/1031/4301569/3912746.pdf  Full year report 2025 
 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---fourth-quarter-and-full-year-report-2025-302677313.html

SOURCE Vitrolife AB (publ)

(END) Dow Jones Newswires

February 03, 2026 02:26 ET (07:26 GMT)